Key facts
- AvenCell’s last known valuation is $227.0M (Oct 2024).
- It has raised $192.4M; the latest was Early Stage VC ($14.6M) in Sep 2025.
- Notable investors include F-Prime Capital, Eight Roads, Novo Holdings, NYBC Ventures, Blackstone Life Sciences — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for AvenCell
- ·The full record, as it builds
Funding rounds
No funding rounds for AvenCell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AvenCell
Developer of T cell-based immunotherapies intended to support cancer treatment. The company focuses on building chimeric antigen receptor T cells for precise targeting of cancer antigens to overcome the limitations of current-generation CAR-T cell therapies with an improved therapeutic window and substantially expand the types of cancer treatable with adoptive cell therapy, including solid tumors, enabling clinical researchers to create a pipeline of autologous and allogeneic universal reprogrammable T cell products, focused initially on hard-to-treat cancers.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2021
- Employees
- 66
- Website
- avencell.com/
- Ownership
- Privately Held (backing)
AvenCell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AvenCell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AvenCell in its N-PORT filings yet. We sweep new filings monthly.